- Home
- ANL vs MDAI Comparison
ANL vs MDAI Comparison
Compare ANL & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- MDAI
- Stock Information
- Founded
- ANL 2004
- MDAI 2013
- Country
- ANL Cayman Islands
- MDAI United States
- Employees
- ANL N/A
- MDAI N/A
- Industry
- ANL
- MDAI Medical/Dental Instruments
- Sector
- ANL
- MDAI Health Care
- Exchange
- ANL Nasdaq
- MDAI Nasdaq
- Market Cap
- ANL 56.0M
- MDAI 51.5M
- IPO Year
- ANL 2023
- MDAI N/A
- Fundamental
- Price
- ANL $1.55
- MDAI $2.92
- Analyst Decision
- ANL Hold
- MDAI Strong Buy
- Analyst Count
- ANL 1
- MDAI 2
- Target Price
- ANL N/A
- MDAI $4.75
- AVG Volume (30 Days)
- ANL 7.4K
- MDAI 674.6K
- Earning Date
- ANL 08-08-2025
- MDAI 08-11-2025
- Dividend Yield
- ANL N/A
- MDAI N/A
- EPS Growth
- ANL N/A
- MDAI N/A
- EPS
- ANL N/A
- MDAI N/A
- Revenue
- ANL N/A
- MDAI $29,962,000.00
- Revenue This Year
- ANL N/A
- MDAI N/A
- Revenue Next Year
- ANL N/A
- MDAI $15.14
- P/E Ratio
- ANL N/A
- MDAI N/A
- Revenue Growth
- ANL N/A
- MDAI 55.21
- 52 Week Low
- ANL $1.10
- MDAI $0.82
- 52 Week High
- ANL $4.10
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- ANL 47.53
- MDAI 75.68
- Support Level
- ANL $1.50
- MDAI $2.56
- Resistance Level
- ANL $1.60
- MDAI $3.21
- Average True Range (ATR)
- ANL 0.07
- MDAI 0.20
- MACD
- ANL 0.02
- MDAI 0.07
- Stochastic Oscillator
- ANL 60.42
- MDAI 89.74
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.